As of June 30, 2026, Wuhan YZY Biopharma Co., Ltd. Class H carries a market capitalization of 739.64M, placing it among publicly traded companies globally. Its enterprise value stands at 812.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 739.64M |
| Enterprise Value | 812.04M |
As of June 30, 2026, Wuhan YZY Biopharma Co., Ltd. Class H has 193.85M shares outstanding.
| Shares Outstanding | 193.85M |
These figures are as of June 30, 2026.
| PB Ratio | -10.93 |
| P/TBV Ratio | -10.93 |
As of June 30, 2026, Wuhan YZY Biopharma Co., Ltd. Class H maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.55 |
| Quick Ratio | 0.32 |
| Debt / Equity | -236.77 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 106.00 |
As of the close on October 23, 2026, Wuhan YZY Biopharma Co., Ltd. Class H's stock has declined approximately 46.40% over the past 52 weeks. The 50-day moving average sits at 5.63, while the 200-day moving average is 6.51.
| 52-Week Price Change | -46.40% |
| 50-Day Moving Average | 5.63 |
| 200-Day Moving Average | 6.51 |
As of June 30, 2026, Wuhan YZY Biopharma Co., Ltd. Class H holds 87.84M in cash and equivalents against 160.24M in total debt, resulting in a net debt position of 72.38M. Total book value stands at -67.68M, with working capital of -121.35M providing operational flexibility.
| Cash & Cash Equivalents | 87.84M |
| Total Debt | 160.24M |
| Net Debt | 72.38M |
| Equity (Book Value) | -67.68M |
| Book Value Per Share | -0.35 |
| Working Capital | -121.35M |
Already premium?